

Technology Appraisal Committee A Interests Register

Topic: Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

Publication Date: 15 May 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
James Fotheringham	TAC A Committee Member	Indirect: Financial	AstraZeneca - James has performed/supported systematic reviews on hypertension, paid to his employer.	06/02/2025	It was agreed that James' declaration would not prevent him from participating in discussions on this appraisal.
Stella O'Brien	TAC C Committee Member	Indirect: Non-Financial	Stella is a member of NHS England's Genomics: Cancer Working Group. She considers additions to the National Genomic Test Directory and the workflow for Genomic Laboratory Hubs. She does not receive any honoraria or other direct/indirect reward for this activity.	03/03/2025	It was agreed that Stella's declaration would not prevent her from participating in discussions on this appraisal.